newsfilter
← Latest News
GlobeNewswire·

Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder

VANCOUVER, British Columbia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ:OPTH) (CSE:OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of